Health insurer group asks Gilead to cut hepatitis C drug price
July 23, 2014 at 16:54 PM EDT
July 23 (Reuters) - A prominent U.S. health insurer trade group on Wednesday called on Gilead Sciences Inc to lower the cost of its hepatitis C drug Sovaldi after the drugmaker reported nearly $3.5 billion in sales for the treatment in its second quarter.